Description

WRW4, a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC50 of 0.23 μM. WRW4 specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–Neuroscience-Neuromodulation–C61H65N15O6—-[1]Bae YS, et al. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J Immunol. 2004;173(1):607-614.–878557-55-2–1104.27–99.40–O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CC5=CNC6=CC=CC=C56)C(N[C@@H](CC7=CNC8=CC=CC=C78)C(N)=O)=O)=O)=O)=O)[C@H](CC9=CNC=CC=CC=C9)N–Neurological Disease–DMSO : 100 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic)–Formyl Peptide Receptor (FPR)—-GPCR/G Protein–Peptides